Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | XDH | P47989 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | USP10 | Q14694 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1386245 | 0.91 | GRIA2 (0.37) | — | |
| SCHEMBL2568465 | 0.87 | SCN9A (0.34) | ALDH1A1GAAPTGS2 | |
| SCHEMBL2573245 | 0.87 | PTGS2 (0.33) | ALDH1A1PTGS2 | |
| SCHEMBL1385594 | 0.86 | SLC1A3 (0.34) | ALDH1A1PTGS2 | |
| SCHEMBL2565037 | 0.85 | ALDH1A1 (0.55) | ALDH1A1MAPTMEN1KMT2AGAA | |
| SCHEMBL1384913 | 0.84 | PTGS2 (0.41) | ALDH1A1PTGS2 | |
| SCHEMBL1385220 | 0.84 | EPHX2 (0.35) | ALDH1A1PTGS2 | |
| SCHEMBL1385853 | 0.84 | PPARG (0.46) | ALDH1A1MAPTMEN1KMT2ACYP1A2 | |
| SCHEMBL2567018 | 0.81 | PTGS2 (0.36) | ALDH1A1PTGS2 | |
| SCHEMBL1384486 | 0.80 | ALDH1A1 (0.33) | ALDH1A1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1583529-B1 | AMINO ACID PHENOXY ETHERS, THEIR PREPARATION AND USES | BEXEL PHARMACEUTICALS INC (US) | 2011-11-09 | — | — | EP | claimed |
| US-6794401-B2 | thiazolidin-2,4-diones or -oxazolidin-2,4-diones; metabolic Syndrome-X; immunological diseases, inflammation, obesity, hyperlipidemia, hypertension, diabetes; increased leptin level; no liver toxicity; inhibits TNF alpha , IL-6 and IL-1 beta; no affinity for PPAR-g; non-adipogenic | BEXEL PHARMACEUTICALS, INC. | 2004-09-21 | — | — | US | claimed |
| WO-2004066964-A9 | AMINO ACID PHENOXY ETHERS | BEXEL PHARMACEUTICALS INC (US) | 2004-09-02 | — | — | WO | claimed |
| US-20040142991-A1 | Amino acid phenoxy ethers | BEXEL PHARMACEUTICALS, INC. | 2004-07-22 | — | — | US | claimed |
| EP-1583529-B1 | AMINO ACID PHENOXY ETHERS, THEIR PREPARATION AND USES | BEXEL PHARMACEUTICALS INC (US) | 2011-11-09 | — | — | EP | disclosed |
| EP-1583529-A4 | AMINO ACID PHENOXY ETHERS | BEXEL PHARMACEUTICALS INC (US) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006125285-A1 | INSULIN SENSITIZATION TO SLOW DOWN PUBERTAL TEMPO AND TO AUGMENT PUBERTAL GROWTH | K.U. LEUVEN RESEARCH AND DEVELOPMENT (BE) | 2006-11-30 | — | — | WO | disclosed |
| EP-1583529-A2 | AMINO ACID PHENOXY ETHERS | Bexel Pharmaceuticals Inc (US) | 2005-10-12 | — | — | EP | disclosed |
| US-20050096366-A1 | thiazolidin-2,4-diones or -oxazolidin-2,4-diones; obesity, inflammation, autoimmune diseases (multiple sclerosis and rheumatoid arthritis); increase the leptin level; no liver toxicity; inhibits TNF- alpha , IL-1, IL-6, IL-1 beta and cyclooxygenase COX-2; no affinity for PPAR-g; non-adipogenic. | BEXEL PHARMACEUTICALS, INC. | 2005-05-05 | — | — | US | disclosed |
| US-6794401-B2 | thiazolidin-2,4-diones or -oxazolidin-2,4-diones; metabolic Syndrome-X; immunological diseases, inflammation, obesity, hyperlipidemia, hypertension, diabetes; increased leptin level; no liver toxicity; inhibits TNF alpha , IL-6 and IL-1 beta; no affinity for PPAR-g; non-adipogenic | BEXEL PHARMACEUTICALS, INC. | 2004-09-21 | — | — | US | disclosed |
| WO-2004066964-A9 | AMINO ACID PHENOXY ETHERS | BEXEL PHARMACEUTICALS INC (US) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004066964-A2 | AMINO ACID PHENOXY ETHERS | BEXEL PHARMACEUTICALS, INC. (US) | 2004-08-12 | — | — | WO | disclosed |
| US-20040142991-A1 | Amino acid phenoxy ethers | BEXEL PHARMACEUTICALS, INC. | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142991-A1 | Amino acid phenoxy ethers | IL4I1, DNPEP, GPR119 | ALDH1A1 3765/4885MAPT 1505/4885MEN1 4683/4885 |
| US-20050096366-A1 | thiazolidin-2,4-diones or -oxazolidin-2,4-diones; obesity, inflammation, autoimmune diseases (multiple sclerosis and rheumatoid arthritis); increase the leptin level; no liver toxicity; inhibits TNF- alpha , IL-1, IL-6, IL-1 beta and cyclooxygenase COX-2; no affinity for PPAR-g; non-adipogenic. | PPARA, PPARG, PPARD | ALDH1A1 263/4885MAPT 3742/4885MEN1 3247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.